STOCK TITAN
  1. Home
  2. Sec-filings
  3. KOD
  4. [Form 4] Kodiak Sciences Inc. Insider Trading Activity

Kodiak Sciences: Baker funds buy 418K shares

The reported prices are weighted averages, with footnotes giving separate execution-price ranges for groups of fund transactions.

Filing Impact
(Very High)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
4

Rhea-AI Filing Summary

Kodiak Sciences Inc. (KOD) reports that 667, L.P. and Baker Brothers Life Sciences, L.P. purchased 418,323 common shares on September 28, 2026, at reported weighted-average prices ranging from $79.4045 to $85.9656 per share. Julian C. Baker and Felix J. Baker, managing members of Baker Bros. Advisors (GP) LLC, may be deemed to have indirect pecuniary interests in shares held by the funds; they disclaim beneficial ownership except to the extent of those interests. No Rule 10b5-1 plan is reported.

Insights

Analyzing...

Insider BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN
Role Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner
Bought 418,323 shs ($34.96M)
Type Security Shares Price Value
Purchase Common Stock F1, F2, F3, F4 534 $79.4045 $42K
Purchase Common Stock F1, F3, F4, F5 8,956 $79.4045 $711K
Purchase Common Stock F2, F3, F4 17 $79.63 $1K
Purchase Common Stock F3, F4, F5 283 $79.63 $23K
Purchase Common Stock F6, F2, F3, F4 884 $79.7076 $70K
Purchase Common Stock F6, F3, F4, F5 14,827 $79.7076 $1.18M
Purchase Common Stock F7, F2, F3, F4 404 $80.2259 $32K
Purchase Common Stock F7, F3, F4, F5 6,783 $80.2259 $544K
Purchase Common Stock F2, F3, F4 61 $80.52 $5K
Purchase Common Stock F3, F4, F5 1,027 $80.52 $83K
Purchase Common Stock F8, F2, F3, F4 1,024 $81.0204 $83K
Purchase Common Stock F8, F3, F4, F5 17,159 $81.0204 $1.39M
Purchase Common Stock F9, F2, F3, F4 338 $81.2019 $27K
Purchase Common Stock F9, F3, F4, F5 5,654 $81.2019 $459K
Purchase Common Stock F10, F2, F3, F4 1,044 $81.3139 $85K
Purchase Common Stock F10, F3, F4, F5 17,490 $81.3139 $1.42M
Purchase Common Stock F11, F2, F3, F4 1,672 $81.8162 $137K
Purchase Common Stock F11, F3, F4, F5 28,028 $81.8162 $2.29M
Purchase Common Stock F2, F3, F4 39 $81.915 $3K
Purchase Common Stock F3, F4, F5 651 $81.915 $53K
Purchase Common Stock F12, F2, F3, F4 101 $82.6822 $8K
Purchase Common Stock F12, F3, F4, F5 1,699 $82.6822 $140K
Purchase Common Stock F13, F2, F3, F4 1,167 $83.1552 $97K
Purchase Common Stock F13, F3, F4, F5 19,554 $83.1552 $1.63M
Purchase Common Stock F14, F2, F3, F4 7,390 $83.9512 $620K
Purchase Common Stock F14, F3, F4, F5 123,888 $83.9512 $10.40M
Purchase Common Stock F15, F2, F3, F4 6,553 $84.8543 $556K
Purchase Common Stock F15, F3, F4, F5 109,842 $84.8543 $9.32M
Purchase Common Stock F16, F2, F3, F4 2,322 $85.9656 $200K
Purchase Common Stock F16, F3, F4, F5 38,932 $85.9656 $3.35M
Holdings After Transaction: Common Stock — 19,515,907 shares (Indirect, See Footnotes)
Footnotes (16)
  1. F1. The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $79.07 to $79.55, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  2. F2. After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  3. F3. Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
  4. F4. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  5. F5. After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
  6. F6. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $79.44 to $80.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  7. F7. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.00 to $80.79, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  8. F8. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.455 to $81.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  9. F9. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.935 to $81.73, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  10. F10. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $81.31 to $81.46, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  11. F11. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $81.27 to $82.22, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  12. F12. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $82.52 to $82.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  13. F13. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $82.66 to $83.38, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  14. F14. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $83.39 to $84.39, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  15. F15. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $84.41 to $85.40, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  16. F16. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.50 to $86.47, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Shares purchased 418,323 shares September 28, 2026
Lowest reported weighted-average price $79.4045 per share Fund purchases on September 28, 2026
Highest reported weighted-average price $85.9656 per share Fund purchases on September 28, 2026
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirect pecuniary interest financial
"may be deemed to have an indirect pecuniary interest"
beneficial ownership regulatory
"disclaim beneficial ownership of the securities held directly by the Funds"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KOD shares did Baker Brothers funds purchase?
667, L.P. and Baker Brothers Life Sciences, L.P. reported purchases of 418,323 Kodiak common shares on September 28, 2026, at reported weighted-average prices from $79.4045 to $85.9656 per share. No Rule 10b5-1 plan is reported.

Who had investment authority over the KOD shares held by the funds?
Baker Bros. Advisors LP had complete and unlimited discretion and authority over the investment and voting power of securities held directly by the funds. Julian C. Baker and Felix J. Baker were managing members of Baker Bros. Advisors (GP) LLC, the adviser's sole general partner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BAKER BROS. ADVISORS LP
(Last)(First)(Middle)
860 WASHINGTON STREET
3RD FLOOR
(Street)
NEW YORK NEW YORK 10014
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Kodiak Sciences Inc. [ KOD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/28/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/28/2026P534A$79.4045(1)1,606,426ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P8,956A$79.4045(1)19,130,090ISee Footnotes(3)(4)(5)
Common Stock09/28/2026P17A$79.631,606,443ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P283A$79.6319,130,373ISee Footnotes(3)(4)(5)
Common Stock09/28/2026P884A$79.7076(6)1,607,327ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P14,827A$79.7076(6)19,145,200ISee Footnotes(3)(4)(5)
Common Stock09/28/2026P404A$80.2259(7)1,607,731ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P6,783A$80.2259(7)19,151,983ISee Footnotes(3)(4)(5)
Common Stock09/28/2026P61A$80.521,607,792ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P1,027A$80.5219,153,010ISee Footnotes(3)(4)(5)
Common Stock09/28/2026P1,024A$81.0204(8)1,608,816ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P17,159A$81.0204(8)19,170,169ISee Footnotes(3)(4)(5)
Common Stock09/28/2026P338A$81.2019(9)1,609,154ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P5,654A$81.2019(9)19,175,823ISee Footnotes(3)(4)(5)
Common Stock09/28/2026P1,044A$81.3139(10)1,610,198ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P17,490A$81.3139(10)19,193,313ISee Footnotes(3)(4)(5)
Common Stock09/28/2026P1,672A$81.8162(11)1,611,870ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P28,028A$81.8162(11)19,221,341ISee Footnotes(3)(4)(5)
Common Stock09/28/2026P39A$81.9151,611,909ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P651A$81.91519,221,992ISee Footnotes(3)(4)(5)
Common Stock09/28/2026P101A$82.6822(12)1,612,010ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P1,699A$82.6822(12)19,223,691ISee Footnotes(3)(4)(5)
Common Stock09/28/2026P1,167A$83.1552(13)1,613,177ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P19,554A$83.1552(13)19,243,245ISee Footnotes(3)(4)(5)
Common Stock09/28/2026P7,390A$83.9512(14)1,620,567ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P123,888A$83.9512(14)19,367,133ISee Footnotes(3)(4)(5)
Common Stock09/28/2026P6,553A$84.8543(15)1,627,120ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P109,842A$84.8543(15)19,476,975ISee Footnotes(3)(4)(5)
Common Stock09/28/2026P2,322A$85.9656(16)1,629,442ISee Footnotes(2)(3)(4)
Common Stock09/28/2026P38,932A$85.9656(16)19,515,907ISee Footnotes(3)(4)(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
BAKER BROS. ADVISORS LP
(Last)(First)(Middle)
860 WASHINGTON STREET
3RD FLOOR
(Street)
NEW YORK NEW YORK 10014
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
667, L.P.
(Last)(First)(Middle)
860 WASHINGTON STREET, 3RD FLOOR
(Street)
NEW YORK NEW YORK 10014
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Baker Bros. Advisors (GP) LLC
(Last)(First)(Middle)
860 WASHINGTON STREET
3RD FLOOR
(Street)
NEW YORK NEW YORK 10014
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Baker Brothers Life Sciences LP
(Last)(First)(Middle)
860 WASHINGTON STREET
3RD FLOOR
(Street)
NEW YORK NEW YORK 10014
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
BAKER FELIX
(Last)(First)(Middle)
860 WASHINGTON STREET
3RD FLOOR
(Street)
NEW YORK NEW YORK 10014
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
BAKER JULIAN
(Last)(First)(Middle)
860 WASHINGTON STREET, 3RD FLOOR
(Street)
NEW YORK NEW YORK 10014
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $79.07 to $79.55, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
2. After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
3. Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
4. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
5. After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
6. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $79.44 to $80.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
7. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.00 to $80.79, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
8. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.455 to $81.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
9. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.935 to $81.73, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
10. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $81.31 to $81.46, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
11. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $81.27 to $82.22, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
12. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $82.52 to $82.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
13. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $82.66 to $83.38, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
14. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $83.39 to $84.39, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
15. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $84.41 to $85.40, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
16. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.50 to $86.47, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Remarks:
Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, the sole general partner of Baker Bros. Advisors LP, is a director of Kodiak Sciences Inc. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Felix J. Baker are deemed directors by deputization of the Issuer. This is the second of three Forms 4 reporting changes in beneficial ownership. Due to space limitations in Form 4 we are thus filing these three Forms 4.
By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing09/30/2026
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing09/30/2026
By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing09/30/2026
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P., /s/ Name: Scott L. Lessing, Title: President09/30/2026
/s/ Felix J. Baker09/30/2026
/s/ Julian C. Baker09/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on KOD

All KOD news

Trending in the feed

MU
Micron Technology, Inc. Reports Record Fiscal Fourth-Quarter and Full-Year 2026 Results Open the live feed